Enovis Refreshes Its Veterinary Laser Flagship as Rehab Hardens Into a Clinic Revenue Line

Enovis launched CT-RevitL on July 13, the next generation of its Companion Animal Health laser therapy platform, built around an intelligent guidance system that standardizes dosing. For clinic operators, the significance is not the hardware spec sheet. It is that the company behind the largest name in veterinary therapeutic lasers is betting pain management and rehab keep maturing into a technician-delivered, protocol-driven service line.

A guided-dosing system is the centerpiece of the new flagship, not raw power

CT-RevitL is a photobiomodulation (PBM) laser system from Enovis Companion Animal Health, the Newark, Delaware division that has spent more than 15 years in veterinary laser therapy and describes itself as the U.S. market leader in the category. The headline feature is COMPASS, an intelligent treatment guidance system the company says delivers precise, calibrated dosing, paired with a redesigned treatment interface and a more mobile form factor.

The system targets the familiar PBM use cases: pain management, accelerated tissue healing, inflammation reduction, and post-operative recovery across musculoskeletal and soft-tissue conditions. U.S. availability began with the July 13 announcement, with international markets to follow in later phases. Pricing was not disclosed.

"CT-RevitL represents the next chapter in our commitment to deliver practical, innovative, evidence-based veterinary care," said Terry Ross, group president of Enovis Prevention and Recovery.

The corporate lineage matters here. Companion Animal Health grew out of LiteCure, the laser maker that human orthopedics company DJO acquired in late 2020. DJO rebranded as Enovis (NYSE: ENOV) in 2022, and the companion animal business now sits inside a medtech operator that runs the same playbook it uses in human prevention and recovery.

Standardized dosing turns laser therapy from an art into a bookable, technician-run service

The economics of laser therapy have always been attractive on paper. Treatment protocols run across multiple sessions, visits are delivered by credentialed technicians rather than veterinarians, and clinics typically sell packages. In a market where DVM hours are the scarcest resource in the building, a recurring service line that barely touches the doctor's schedule is exactly what practice managers want more of.

The persistent problem has been variability. PBM outcomes depend heavily on dosing and technique, which differ from operator to operator, and that inconsistency is a big reason laser programs stall after the initial enthusiasm fades. A medical director who cannot count on repeatable delivery is reluctant to build marketing, pricing, and staffing around the service.

That is the gap COMPASS is aimed at. If guided dosing genuinely standardizes delivery, the clinical conversation shifts from "our technician is good at this" to "our protocol produces consistent results." Standardization is what turns an ancillary gadget into a defensible service line, the same transition that made dental workflows and in-house diagnostics durable revenue categories.

There is also a supplier-side read. Enovis built its human business on installed-base economics: equipment refresh cycles, training programs, and evidence generation that keeps clinicians inside the ecosystem. A next-generation flagship gives its veterinary installed base, accumulated over more than a decade of LiteCure and Companion placements, a concrete upgrade path. Whether or not new clinics adopt, the refresh cycle alone is meaningful revenue.

The launch says something about where device makers see growth, too. Diagnostics get most of the industry's attention, but therapy hardware sits directly in the revenue-per-visit conversation at a moment when clinics are fighting declining visit counts by expanding what each patient relationship is worth.

Pricing, trade-ins, and outcomes data will show whether this is an upgrade cycle or an expansion play

The undisclosed price is the first thing to watch. A premium flagship with aggressive trade-in terms would signal Enovis is mining its existing installed base. Accessible pricing aimed at general practices that never bought a therapy laser would signal a genuine expansion bet on rehab as a mainstream service line.

The second signal is data. A guidance system that calibrates dosing is also, potentially, a system that captures treatment data at scale. If Enovis turns COMPASS into published outcomes evidence, that strengthens the case for laser therapy in standard-of-care discussions and, eventually, in pet insurance reimbursement conversations as insured pet counts grow.

Finally, watch the consolidators. Corporate veterinary groups standardizing a protocolized rehab offering across hundreds of locations would change the demand curve for this category overnight, and guided-dosing hardware is precisely what makes that kind of multi-site rollout plausible. International phases of the launch will indicate how quickly Enovis wants to press that opportunity beyond the U.S.

Source: Enovis Companion Animal Health launch announcement via GlobeNewswire